Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, showcased new clinical evidence supporting Extracorporeal Blood Purification at the 6th Asia Pacific Acute Kidney Injury & Continuous Renal Replacement Therapy Conference 2025 (APAC AKI CRRT Conference 2025) in Bangkok. The company, known for its leadership in renal care and multi-organ support, participated as a sponsor for a consensus paper on Extracorporeal Blood Purification as well as a separate study involving intensive care patients. Through these initiatives, Vantive reinforced its commitment to supporting clinicians in managing sepsis and hyperinflammatory conditions challenges that remain critical in intensive care units across the Asia-Pacific region, including Malaysia.
Developed by a group of experts from across the region, the two papers presented at the conference provide new perspectives on managing sepsis and multi-organ failure in critically ill patients. They offer clinical insights aimed at equipping healthcare professionals with the capabilities needed to act decisively in high-pressure care settings.
Professor Nattachai Srisawat, MD, PhD, from Thailand
Professor Nattachai Srisawat, MD, PhD, from Thailand, lead author of the consensus, emphasized the importance of collaboration in advancing clinical care. “Our work to develop the consensus and promote its recommendations among clinicians across Asia Pacific at the AKI CRRT conference is a testament to the power of collaboration. By partnering with Vantive, we are able to take the latest research in acute kidney injury and translate it into practical, life-saving therapies that directly benefit patients in Thailand, Malaysia, and beyond. This is about building a regional network of expertise to combat organ failure more effectively,” he said.
Adding to this, Professor Pham Chi Ngoc Thao of Cho Ray Hospital, Vietnam, who was also involved in the consensus, noted, “In critical care, every minute counts. Vantive’s commitment to advancing multi-organ support gives clinicians a new level of confidence in the most challenging situations. This collaboration is crucial for institutions like Cho Ray Hospital, as it empowers us to adopt cutting-edge technologies and share our experiences to improve outcomes for our most critically ill patients in Vietnam, Malaysia, and more.”
Professor Pham Chi Ngoc Thao of Cho Ray Hospital, Vietnam
As a vital organ therapy company, Vantive continues to deliver on its mission to extend lives and expand possibilities through innovation in continuous renal replacement therapy (CRRT) and multi-organ support. At the APAC AKI CRRT Conference in Bangkok, held from October 2 to 4, 2025, Vantive highlighted its ongoing research and technological advancements aimed at enhancing the effectiveness of critical care therapies. The company’s active role in the regional forum underscores its long-standing dedication to advancing medical knowledge, strengthening hospital partnerships, and investing in education and clinical research particularly in Malaysia, where acute kidney injury remains a pressing concern in intensive care units, contributing to extended hospital stays and higher treatment costs.
Dr. Kuljinder Singh, APAC Medical Director at Vantive, affirmed the company’s commitment to medical innovation and collaboration. “As a leader in vital organ therapies, we are proud to work with the clinical community to advance lifesaving critical care therapies with systems capable of delivering continuous renal replacement therapy as well as multi-organ support. We continue to pursue novel diagnostic and therapeutic options, including a new approach to sepsis management,” he said.
Dr. Kuljinder Singh, APAC Medical Director at Vantive
Vantive’s participation at the 6th APAC AKI CRRT Conference reflects its dedication to advancing the science of critical care and fostering partnerships that empower clinicians across Asia Pacific to improve patient outcomes and redefine standards in organ support therapies.
